|
1
|
Adès L, Itzykson R and Fenaux P:
Myelodysplastic syndromes. Lancet. 383:2239–2252. 2014.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Mitani K: Molecular pathogenesis of MDS.
Rinsho Ketsueki. 50:1325–1331. 2009.PubMed/NCBI(In Japanese).
|
|
3
|
Malcovati L, Hellström-Lindberg E, Bowen
D, Adès L, Cermak J, Del Cañizo C, Della Porta MG, Fenaux P,
Gattermann N, Germing U, et al: European Leukemia Net: Diagnosis
and treatment of primary myelodysplastic syndromes in adults:
Recommendations from the European LeukemiaNet. Blood.
122:2943–2964. 2013.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Cheson BD, Greenberg PL, Bennett JM, et
al: Clinical application and proposal for modification of the
International Working Group (IWG) response criteria in
myelodysplasia. Blood. 108:419–425. 2006.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Cogle CR, Craig BM, Rollison DE and List
AF: CR C. Incidence of the myelodysplastic syndromes using a novel
claims-based algorithm: High number of uncaptured cases by cancer
registries. Blood. 117:7121–7125. 2011.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Greenberg PL, Tuechler H, Schanz J, Sanz
G, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus
F, et al: Revised international prognostic scoring system for
myelodysplastic syndromes. Blood. 120:2454–2465. 2012.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Killick SB, Carter C, Culligan D, Dalley
C, Das-Gupta E, Drummond M, Enright H, Jones GL, Kell J, Mills J,
et al: British Committee for Standards in Haematology: Guidelines
for the diagnosis and management of adult myelodysplastic
syndromes. Br J Haematol. 164:503–525. 2014.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Greenberg PL, Stone RM, Al-Kali A, et al:
Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice
Guidelines in Oncology. J Natl Compr Canc Netw. 15:60–87.
2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Macedo LC, Silvestre AP, Rodrigues C, de
Alencar JB, Zacarias JM, Ambrosio-Albuquerque EP, Sell AM and
Visentainer JE: Genetics factors associated with myelodysplastic
syndromes. Blood Cells Mol Dis. 55:76–81. 2015.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Grisendi S, Bernardi R, Rossi M, Cheng K,
Khandker L, Manova K and Pandolfi PP: Role of nucleophosmin in
embryonic development and tumorigenesis. Nature. 437:147–153.
2005.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Schneider F, Hoster E, Unterhalt M,
Schneider S, Dufour A, Benthaus T, Mellert G, Zellmeier E,
Bohlander SK, Feuring-Buske M, et al: NPM1 but not FLT3-ITD
mutations predict early blast cell clearance and CR rate in
patients with normal karyotype AML (NK-AML) or high-risk
myelodysplastic syndrome (MDS). Blood. 113:5250–5253.
2009.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Wimmer K, Vinatzer U, Zwirn P, Fonatsch C
and Wieser R: Comparative expression analysis of the antagonistic
transcription factors EVI1 and MDS1-EVI1 in murine tissues and
during in vitro hematopoietic differentiation. Biochem Biophys Res
Commun. 252:691–696. 1998.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Graubert T and Walter MJ: Genetics of
myelodysplastic syndromes: New insights. Hematology (Am Soc Hematol
Educ Program). 2011:543–549. 2011.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Bagatell R and Whitesell L: Altered Hsp90
function in cancer: A unique therapeutic opportunity. Mol Cancer
Ther. 3:1021–1030. 2004.PubMed/NCBI
|
|
15
|
Kamal A, Thao L, Sensintaffar J, Zhang L,
Boehm MF, Fritz LC and Burrows FJ: A high-affinity conformation of
Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature.
425:407–410. 2003.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Flandrin P, Guyotat D, Duval A, Cornillon
J, Tavernier E, Nadal N and Campos L: Significance of heat-shock
protein (HSP) 90 expression in acute myeloid leukemia cells. Cell
Stress Chaperones. 13:357–364. 2008.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Forsythe HL, Jarvis JL, Turner JW, Elmore
LW and Holt SE: Stable association of hsp90 and p23, but Not hsp70,
with active human telomerase. J Biol Chem. 276:15571–15574.
2001.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Pinkerton DM, Chow S, Eisa NH, Kainth K,
Vanden Berg TJ, Burns JM, Guddat LW, Savage GP, Chadli A and
Williams CM: Synthesis of the seco-Limonoid BCD Ring System
Identifies a Hsp90 Chaperon Machinery (p23) Inhibitor. Chemistry.
25:1451–1455. 2019.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Duval A, Olaru D, Campos L, Flandrin P,
Nadal N and Guyotat D: Expression and prognostic significance of
heat-shock proteins in myelodysplastic syndromes. Haematologica.
91:713–714. 2006.PubMed/NCBI
|
|
20
|
Flandrin-Gresta P, Solly F, Aanei CM,
Cornillon J, Tavernier E, Nadal N, Morteux F, Guyotat D, Wattel E
and Campos L: Heat Shock Protein 90 is overexpressed in high-risk
myelodysplastic syndromes and associated with higher expression and
activation of Focal Adhesion Kinase. Oncotarget. 3:1158–1168.
2012.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Chiosis G, Timaul MN, Lucas B, Munster PN,
Zheng FF, Sepp-Lorenzino L and Rosen N: A small molecule designed
to bind to the adenine nucleotide pocket of Hsp90 causes Her2
degradation and the growth arrest and differentiation of breast
cancer cells. Chem Biol. 8:289–299. 2001.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Lundgren K, Zhang H, Brekken J, Huser N,
Powell RE, Timple N, Busch DJ, Neely L, Sensintaffar JL, Yang YC,
et al: BIIB021, an orally available, fully synthetic small-molecule
inhibitor of the heat shock protein Hsp90. Mol Cancer Ther.
8:921–929. 2009.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Jiang J, Wang B, Li J, Ye B, Lin S, Qian
W, Shan L and Efferth T: Total coumarins of Hedyotis diffusa
induces apoptosis of myelodysplastic syndrome SKM-1 cells by
activation of caspases and inhibition of PI3K/Akt pathway proteins.
J Ethnopharmacol. 196:253–260. 2017.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Qin T, Castoro R, El Ahdab S, Jelinek J,
Wang X, Si J, Shu J, He R, Zhang N, Chung W, et al: Mechanisms of
resistance to decitabine in the myelodysplastic syndrome. PLoS One.
6(e23372)2011.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Di H, Liu D, Gao X, Xu Y, Wang Y and Wang
Z: [TCM Diagnosis and Treatment Status of Myelodysplastic
Syndrome]. World Chinese Medicine. 9:1557–1560. 2014.
|
|
26
|
Lee HZ, Bau DT, Kuo CL, Tsai RY, Chen YC
and Chang YH: Clarification of the phenotypic characteristics and
anti-tumor activity of Hedyotis diffusa. Am J Chin Med.
39:201–213. 2011.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Meng QX, Roubin RH and Hanrahan JR:
Ethnopharmacological and bioactivity guided investigation of five
TCM anticancer herbs. J Ethnopharmacol. 148:229–238.
2013.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Niu Y and Meng QX: Chemical and
preclinical studies on Hedyotis diffusa with anticancer
potential. J Asian Nat Prod Res. 15:550–565. 2013.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Wang M, Jia M, Ma Y, Jiang G, Tang S and
Xia L: Determination of coumarins content in Radix Angelicae
dahuricae by HPLC and UV. Zhong Yao Cai. 27:826–828.
2004.PubMed/NCBI(In Chinese).
|
|
31
|
Cazzola M: Myelodysplastic Syndromes. N
Engl J Med. 383:1358–1374. 2020.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Garg R, Faderl S, Garcia-Manero G, Cortes
J, Koller C, Huang X, York S, Pierce S, Brandt M, Beran M, et al:
Phase II study of rabbit anti-thymocyte globulin, cyclosporine and
granulocyte colony-stimulating factor in patients with aplastic
anemia and myelodysplastic syndrome. Leukemia. 23:1297–1302.
2009.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Saunthararajah Y, Nakamura R, Wesley R,
Wang QJ and Barrett AJ: A simple method to predict response to
immunosuppressive therapy in patients with myelodysplastic
syndrome. Blood. 102:3025–3027. 2003.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Santini V: Treatment of low-risk
myelodysplastic syndromes. Hematology (Am Soc Hematol Educ
Program). 2016:462–469. 2016.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Gibbs JB: Mechanism-based target
identification and drug discovery in cancer research. Science.
287:1969–1973. 2000.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Ganser A, Passweg J, Stadler M,
Dobbelstein C and Weissinger EM: Immunosuppressive treatment
strategies in low-risk MDS. Cancer Treat Rev. 33:S11–S14. 2007.
|
|
37
|
Cogulu O, Kosova B, Gunduz C, Karaca E,
Aksoylar S, Erbay A, Karapinar D, Vergin C, Vural F, Tombuloglu M,
et al: The evaluation of hTERT mRNA expression in acute leukemia
children and 2 years follow-up of 40 cases. Int J Hematol.
87:276–283. 2008.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Taldone T, Sun W and Chiosis G: Discovery
and development of heat shock protein 90 inhibitors. Bioorg Med
Chem. 17:2225–2235. 2009.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Wang B, Lin SY, Shen YY, Wu LQ, Chen ZZ,
Li J, Chen Z, Qian WB and Jiang JP: Pure total flavonoids from
Citrus paradisi Macfadyen act synergistically with arsenic trioxide
in inducing apoptosis of Kasumi-1 leukemia cells in vitro. J
Zhejiang Univ Sci B. 16:580–585. 2015.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Wang B, Zhang Y, Shen Y, Wu L, Zhou Y and
Lin S: [Downregulation of hTERT with Drug Combination of HDE and
BIIB021 Efficiently Inhibit Cell Proliferation of and Induce
Apoptosis in Myelodysplastic Syndromes]. 2019 Annual Meeting of the
Hematology Specialty Committee of Zhejiang Integrative Medicine
Association: 233, 2019.
|
|
41
|
Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE
and Gottesman MM: P-glycoprotein: From genomics to mechanism.
Oncogene. 22:7468–7485. 2003.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Glavinas H, Krajcsi P, Cserepes J and
Sarkadi B: The role of ABC transporters in drug resistance,
metabolism and toxicity. Curr Drug Deliv. 1:27–42. 2004.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Larsen AK, Escargueil AE and Skladanowski
A: Resistance mechanisms associated with altered intracellular
distribution of anticancer agents. Pharmacol Ther. 85:217–229.
2000.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Varma MV, Ashokraj Y, Dey CS and
Panchagnula R: P-glycoprotein inhibitors and their screening: A
perspective from bioavailability enhancement. Pharmacol Res.
48:347–359. 2003.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Zhang H, Neely L, Lundgren K, Yang YC,
Lough R, Timple N and Burrows F: BIIB021, a synthetic Hsp90
inhibitor, has broad application against tumors with acquired
multidrug resistance. Int J Cancer. 126:1226–1234. 2010.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Fang T, Yan YX, Yang Y, Lv YX, Chang QQ
and Zhang DD: Ethyl Acetate Fraction from Hedyotis diffusa
plus Scutellaria barbata Suppresses Migration of
Bone-Metastatic Breast Cancer Cells via OPN-FAK/ERK/NF-κB Axis.
Evid Based Complement Alternat Med. 2020(3573240)2020.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Chen Z, Wang B, Qiu M, Lin SY and Xiong H:
[Proliferation Inhibition and Its Mechanism of Total Coumarins on
Leukemia Cells]. Chinese Pharmaceutical Journal. 52:1503–1509.
2017.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Chen Z, Lin S, Jiang J, et al: [Inhibitory
Effect of Total Coumarins of Hedyotis diffusa Willd on the Growth
of AML Cell Line Kasumi-1]. Chinese Journal of Integrated
Traditional and Western Medicine. 37:1089–1094. 2017.
|
